Long-term evolution and predictive factors of mild inflammatory bowel disease

被引:11
|
作者
Reenaers, C. [1 ]
Pirard, C. [1 ]
Vankemseke, C. [1 ]
Latour, P. [1 ]
Belaiche, J. [1 ]
Louis, E. [1 ]
机构
[1] Univ Hosp Liege, Dept Gastroenterol, Liege, Belgium
关键词
Benign evolution; mild IBD; complication; predictive factor; CROHNS-DISEASE; ULCERATIVE-COLITIS; COLORECTAL-CANCER; CLINICAL-COURSE; RISK; CLASSIFICATION; INFECTIONS; MORTALITY; COLECTOMY; BEHAVIOR;
D O I
10.3109/00365521.2015.1128965
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background Crohn's disease (CD) and ulcerative colitis (UC) are potentially progressive diseases. Few data are available on the prevalence and the factors associated with mild inflammatory bowel diseases (IBD). Aim Our aim was to assess the natural history of mild CD and mild UC and to identify predictive factors of mild evolution over the long term. Methods Retrospective study of IBD patients registered in the database of the university hospital CHU of Liege, Belgium. Mild CD was defined as an inflammatory luminal disease (no stricture, abdominal or perianal fistulae) requiring no immunomodulator (IM), anti-TNF and no surgery. Mild UC was defined as no requirement for IM, anti-TNF and no colectomy. Results Four hundred and seventy-three CD and 189 UC were included (median follow-up: 13 and 11 years respectively). At 1 year, 147 patients had mild CD. At 5 years and the maximum follow-up, 56% and 13% patients still had mild CD, respectively. At 1 year, 142 patients had mild UC. At 5 years and the maximum follow-up, 72% and 44% still had a mild UC, respectively. Factors associated with long-term mild CD and UC were older age at diagnosis and absence of corticosteroids in the first year. In UC proctitis location was associated with mild UC. Conclusions In this cohort, 90% of CD patients and 3/4 of UC with mild disease at 1 year lost their mild disease status over time. An old age at diagnosis was predictive of the persistence of a mild CD and UC.
引用
收藏
页码:712 / 719
页数:8
相关论文
共 50 条
  • [31] Long-term Clinical Experience with Vedolizumab in Patients with Inflammatory Bowel Disease
    Parikh, Asit
    Fox, Irving
    Leach, Timothy
    Xu, Jing
    Scholz, Catherine
    Patella, Michael
    Feagan, Brian G.
    INFLAMMATORY BOWEL DISEASES, 2013, 19 (08) : 1691 - 1699
  • [32] The Loneliness of Long-Term Thiopurine Monotherapy for Patients with Inflammatory Bowel Disease
    Lopez, Robert N.
    Day, Andrew S.
    DIGESTIVE DISEASES AND SCIENCES, 2021, 66 (05) : 1390 - 1391
  • [33] Juvenile-onset inflammatory bowel disease: long-term outcome
    Ferguson, A
    Sedgwick, D
    TRENDS IN INFLAMMATORY BOWEL DISEASE THERAPY 1996, 1997, : 207 - 214
  • [34] An update on the safety of long-term vedolizumab use in inflammatory bowel disease
    Honap, Sailish
    Netter, Patrick
    Danese, Silvio
    Peyrin-Biroulet, Laurent
    EXPERT OPINION ON DRUG SAFETY, 2023,
  • [35] Cochlear implantation in the elderly: outcomes, long-term evolution, and predictive factors
    Garcia-Iza, Leire
    Martinez, Zurine
    Ugarte, Ane
    Fernandez, Mercedes
    Altuna, Xabier
    EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY, 2018, 275 (04) : 913 - 922
  • [36] Cochlear implantation in the elderly: outcomes, long-term evolution, and predictive factors
    Leire Garcia-Iza
    Zuriñe Martinez
    Ane Ugarte
    Mercedes Fernandez
    Xabier Altuna
    European Archives of Oto-Rhino-Laryngology, 2018, 275 : 913 - 922
  • [37] Cyclosporine therapy in inflammatory bowel disease - Short-term and long-term results
    Gurudu, SR
    Griffel, LH
    Gialanella, RJ
    Das, KM
    JOURNAL OF CLINICAL GASTROENTEROLOGY, 1999, 29 (02) : 151 - 154
  • [38] Predictive factors of bone loss in inflammatory bowel disease
    Hammami, A.
    Hasnaoui, B.
    Ksiaa, M.
    Jaziri, H.
    Elleuch, N.
    Brahem, A.
    Ajmi, S.
    Ben Slama, A.
    Jmaa, A.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S222 - S222
  • [39] Long-term psychosocial outcomes reported by children and adolescents with inflammatory bowel disease
    Mackner, LM
    Crandall, WV
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2005, 100 (06): : 1386 - 1392
  • [40] Long-term treatment with infliximab in inflammatory bowel disease: safety and tolerability issues
    Caviglia, Renato
    Boskoski, Ivo
    Cicala, Michele
    EXPERT OPINION ON DRUG SAFETY, 2008, 7 (05) : 617 - 632